A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
AffiliationOncology Division, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.
MetadataShow full item record
AbstractPyridoxine is frequently used to treat capecitabine-induced hand-foot syndrome (HFS), although the evidence of benefit is lacking. We performed a randomised placebo-controlled trial to determine whether pyridoxine could avoid the need for capecitabine dose modifications and improve outcomes.
CitationA randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. 2012, 107 (4):585-7 Br J Cancer
JournalBritish Journal of Cancer